Interview with Selwyn Kahanovitz, CEO, Litha Healthcare Group Limited
Mr Kahanovitz, Focus Reports came to South Africa in 2005 to produce a similar report on the South African pharmaceutical industry. Could you come back for us on the main…
Address: No 106, 16th Road, Midrand, 1686, Gauteng, South Africa
Tel: +27 11 516 1700
Web: http://www.lithahealthcare.co.za/
Litha Healthcare Group Limited is the result of the successful acquisition by Myriad Medical Holdings of Litha Healthcare Holdings (Proprietary) Limited in 2010.
Litha is a diversified healthcare company, with headquarters in Johannesburg, South Africa. Established in 1992 and with over 340 employees nationally, we are the only truly diversified Healthcare group listed on the Johannesburg Stock Exchange.
Litha Healthcare Group is divided into three Divisions;
Litha Biotech
Litha Medical
Litha Pharma
Within each Division there are 100% owned business units with the exception of The Biovac Institute which is a Public Private Partnership (PPP) between the SA Government and The Biovac Consortium.
Each Division is lead by a Divisional CEO. Litha Healthcare Group Limited provides healthcare solutions to hospitals, clinics, specialists pharmacies and general and allied practitioners either through distribution networks or directly.
The group’s diversified businesses include the following areas of healthcare:
Biotechnology : Vaccines
Medical devices : Consumables and Equipment
Pharmaceuticals : Generic, Ethical and Complimentary
Mr Kahanovitz, Focus Reports came to South Africa in 2005 to produce a similar report on the South African pharmaceutical industry. Could you come back for us on the main…
Tremendous strides have been made in both treatment and prevention of AIDS and it is no longer among the 10 leading causes of death globally, however an estimated 39 million…
Dr Benji Pretorius, the founder of Erada Technology Alliance and a malaria survivor himself, shares his insights into why the development of a truly effective malaria vaccine will only succeed…
Writing in the July 2023 edition of DIA’s Global Forum magazine, Nevena Miletic of Roche and the IFPMA’s Africa Regulatory Network and Ian Hudson from the Bill and Melinda Gates…
The third and final piece in Lenias Hwenda of Medicines for Africa’s series looking back at the challenges and successes of HIV/AIDS treatments over the past 40 years and potential…
The second in a three-part series looking back at the challenges and successes of HIV/AIDS treatments over the past 40 years and potential medical breakthroughs to come (read part one…
In the first of a series looking back at the challenges and successes of HIV/AIDS treatments over the past 40 years and potential medical breakthroughs to come, Lenias Hwenda of…
During the COVID-19 pandemic discussions around increasing access to medicines for low and middle-income countries (LMICs) were often centred on compulsory licensing. As a result, pharma companies were up in…
As part of a special focus on drug development and clinical research in Africa in February 2023’s DIA Global Forum magazine, Lisa Ursella Collins of Innomas Clinical Research, Leslie Sam…
Roughly half of Africa’s 1.1 billion people lack regular access to even the most essential medicines and most of Sub-Saharan Africa depends on imports which make up as much as…
Speaking exclusively to PharmaBoardroom, Medicines for Africa’s Lenias Hwenda gives a comprehensive overview of the African Medicines Agency, why such a regulatory body was needed, how it differs from the…
Lenias Hwenda of Medicines for Africa examines the true impact of access to medicine initiatives in Africa, noting that many of the measures takes are often cosmetic and leave a…
Some of the top pharma news coming out of South Africa including Afrigen’s partnership with US National Institutes of Health (NIH), BioNTech’s efforts to bring an mRNA start-to-finish vaccine manufacturing network…
See our Cookie Privacy Policy Here
